HBW Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

In Brief: Givaudan-Roure

This article was originally published in The Rose Sheet

Executive Summary

Givaudan-Roure: Geoffrey Webster to president, worldwide fragrance division, effective Jan. 1, 1999, following the retirement of Givaudan-Roure CEO Jean Amic, the Roche division announced Oct. 6. Webster, who joined Roure (prior to the merger) in 1972, serves as the supplier's North American president and general manager. A successor to Webster has not been named. Effective Jan. 1, 1998, following more than 33 years with the company, Amic will step down as CEO but will continue to serve as president of the fragrance division and will become vice chairman of the Givaudan-Roure board. The company has tapped Roche Vitamins Marketing Director Kuno Sommer to succeed Amic as CEO. Givaudan-Roure noted the appointments reflect Roche's strong commitment to its fragrance supply business, and should "put to rest" any thoughts that Roche plans to exit that arena...
Advertisement
Advertisement
UsernamePublicRestriction

Register

RS004732

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel